Jeffrey Goldberg, MD
Glaucoma Specialist · Stanford, CANPI 1417158114
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $43,976 of the $56,738 with a category attached, or 77.5%. It is spread thinly across 22 manufacturers, the largest accounting for just 20.7%.
Across 85 payments — averaging $667.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurotech Pharmaceuticals, Inc.$12K
- Aerie Pharmaceuticals, Inc.$11K
- Carl Zeiss Meditec, Inc.$11K
- Alcon Research LLC$7K
- Thea Pharma Inc.$4K
- F. Hoffmann-la Roche AG$2K
- plus $10K from 16 others
Across 1 payment — averaging $48,336 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Carl Zeiss Meditec, Inc.$48K
What the payments were for
- Consulting fees$43,97678%
- Speaking & faculty fees$6,60012%
- Travel & lodging$2,7765%
- Food & beverage$3,3516%
- Gifts$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurotech Pharmaceuticals, Inc. | 2 | $11,725 |
| Aerie Pharmaceuticals, Inc. | 16 | $11,119 |
| Carl Zeiss Meditec, Inc. | 14 | $10,888 |
| Alcon Research LLC | 5 | $6,945 |
| Thea Pharma Inc. | 3 | $4,250 |
| F. Hoffmann-la Roche AG | 1 | $2,178 |
| PTC Therapeutics, Inc. | 1 | $2,000 |
| Kowa Pharmaceuticals America, Inc. | 1 | $1,500 |
| Alcon | 17 | $1,471 |
| Regeneron | 2 | $1,381 |
| Genentech, Inc. | 1 | $1,120 |
| Biocryst Pharmaceuticals, Inc. | 1 | $843 |
| Glaukos Corporation | 5 | $391 |
| Sight Sciences, Inc. | 7 | $366 |
| Nova Eye, Inc. | 1 | $314 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $57 |
| Dompe US, Inc. | 1 | $37 |
| Carl Zeiss Meditec USA, Inc. | 1 | $37 |
| Iridex Corporation | 1 | $34 |
| Nobel Biocare USA | 1 | $32 |
| Mallinckrodt Enterprises LLC | 1 | $29 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENCELTO$11,725
- CIRRUS HD-OCT$7,630
- CLARUS$3,400
- IYUZEH$2,550
- FORUM$2,380
- Humphrey HFA$2,380
- PLEX Elite 9000$2,380
- Humphrey FDT$1,700
- VISUCAM Fundus Cameras$1,700
- Rocklatan$1,227
- Rhopressa$1,148
- Lucentis$1,120
- CALLISTO eye$550
- OPMI Lumera 700$550
- IOLMaster 700$550
- RESCAN 700$206
- OMNI(R) SURGICAL SYSTEM (US)$127
How this compares
$56,738 in reported general payments places this provider in the 85th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 14 | $6,292 |
| Brimonidine Tartrate | 11 | $2,320 |
| Prednisolone Acetate | 12 | $638 |
| Latanoprost | 43 | $415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa | $11,119 | $6,29214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Stanford
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Yang SunStanford$2K
- Vikram ShankarStanford$1K
- Gala BeykinStanford$379
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.